NASDAQ •
Healthcare •
Drug Manufacturers - Specialty & Generic •
Quote as of 06/22/2026 14:40
Company Profile
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
ExchangeNASDAQ
Market Capitalization287.04 mln
Float262 mln
Earnings Date07/30/2026
Piotroski F-Score
5
/ 9
Neutral
Beneish M-Score
-3.37
Reliable
1-Year Forecast
4.20
Transformational upside
Relative Strength
93
/ 100
Top performer
Debt / Equity
1.86
High leverage
Pre-Tax Margin
2%
Break-even
Business Description
Akebia Therapeutics is a Massachusetts-based medical company founded in 2007 that develops and sells treatments for people living with kidney disease. Its two approved medicines help patients manage anemia and high phosphorus levels associated with chronic kidney disease, while two additional drugs are currently being tested in clinical trials for conditions including kidney injury following heart surgery and an eye disorder affecting premature newborns. The company markets its products across multiple regions through licensing partnerships with pharmaceutical firms in Japan, Asia, and other territories.
